Galapagos NV (NASDAQ:GLPG) Given Consensus Rating of "Reduce" by Analysts

Galapagos NV (NASDAQ:GLPG - Get Free Report) has been given an average recommendation of "Reduce" by the nine research firms that are presently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $31.3333.

Several equities research analysts recently commented on GLPG shares. Leerink Partners set a $40.00 price objective on Galapagos and gave the company an "outperform" rating in a research report on Tuesday, October 21st. Wall Street Zen raised Galapagos from a "sell" rating to a "hold" rating in a research report on Sunday, November 23rd. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Galapagos in a report on Wednesday, October 8th. Leerink Partnrs upgraded shares of Galapagos from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, October 22nd. Finally, Royal Bank Of Canada boosted their price objective on shares of Galapagos from $28.00 to $32.00 and gave the company a "sector perform" rating in a report on Friday, November 7th.

View Our Latest Report on Galapagos

Hedge Funds Weigh In On Galapagos

Hedge funds and other institutional investors have recently modified their holdings of the company. State of Wyoming purchased a new position in shares of Galapagos in the 2nd quarter worth $28,000. GAMMA Investing LLC lifted its holdings in Galapagos by 79.4% in the third quarter. GAMMA Investing LLC now owns 1,473 shares of the biotechnology company's stock valued at $51,000 after acquiring an additional 652 shares during the period. Quadrant Capital Group LLC purchased a new position in Galapagos in the third quarter worth about $134,000. Squarepoint Ops LLC bought a new stake in shares of Galapagos during the 3rd quarter valued at about $211,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Galapagos during the 3rd quarter valued at about $212,000. 32.46% of the stock is owned by institutional investors.

Galapagos Stock Up 1.3%

Shares of NASDAQ GLPG opened at $31.77 on Thursday. The firm has a market cap of $2.09 billion, a P/E ratio of -20.24 and a beta of 0.18. Galapagos has a twelve month low of $22.36 and a twelve month high of $37.78. The company has a 50 day moving average of $32.45 and a 200 day moving average of $31.29.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.

Featured Articles

• Five stocks we like better than Galapagos
• How to Know if a Stock Pays Dividends and When They Are Paid Out
• 3 Stocks Poised to Benefit From Google’s AI Breakthough
• Do ETFs Pay Dividends? What You Need to Know
• Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026
• Large Cap Stock Definition and How to Invest
• 3 Stocks You’ll Wish You Bought Before 2026

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Galapagos Right Now?

Before you consider Galapagos, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.

While Galapagos currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here